These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30446650)

  • 1. A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation.
    Reeves DB; Duke ER; Wagner TA; Palmer SE; Spivak AM; Schiffer JT
    Nat Commun; 2018 Nov; 9(1):4811. PubMed ID: 30446650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latently infected cell activation: a way to reduce the size of the HIV reservoir?
    Forde J; Volpe JM; Ciupe SM
    Bull Math Biol; 2012 Jul; 74(7):1651-72. PubMed ID: 22562387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.
    Vandergeeten C; Fromentin R; Chomont N
    Cytokine Growth Factor Rev; 2012; 23(4-5):143-9. PubMed ID: 22743037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV Persistence, Latency, and Cure Approaches: Where Are We Now?
    Chou TC; Maggirwar NS; Marsden MD
    Viruses; 2024 Jul; 16(7):. PubMed ID: 39066325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential implication of residual viremia in patients on effective antiretroviral therapy.
    Sahu GK
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):25-35. PubMed ID: 25428885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What can we do to reduce the viral reservoir in HIV-1-infected individuals?
    Pohlmeyer CW; Walker-Sperling VE; Blankson JN
    Future Microbiol; 2016 Jul; 11():839-42. PubMed ID: 27416850
    [No Abstract]   [Full Text] [Related]  

  • 7. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
    Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
    J Virol; 2018 May; 92(9):. PubMed ID: 29444937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
    Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
    PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the Latent Reservoir for HIV-1.
    Sengupta S; Siliciano RF
    Immunity; 2018 May; 48(5):872-895. PubMed ID: 29768175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Latency reversal plus natural killer cells diminish HIV reservoir in vivo.
    Kim JT; Zhang TH; Carmona C; Lee B; Seet CS; Kostelny M; Shah N; Chen H; Farrell K; Soliman MSA; Dimapasoc M; Sinani M; Blanco KYR; Bojorquez D; Jiang H; Shi Y; Du Y; Komarova NL; Wodarz D; Wender PA; Marsden MD; Sun R; Zack JA
    Nat Commun; 2022 Jan; 13(1):121. PubMed ID: 35013215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.
    Darcis G; Berkhout B; Pasternak AO
    Viruses; 2020 Apr; 12(5):. PubMed ID: 32349381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
    Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
    J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy.
    Lee SA; Bacchetti P; Chomont N; Fromentin R; Lewin SR; O'Doherty U; Palmer S; Richman DD; Siliciano JD; Yukl SA; Deeks SG; Burbelo PD
    PLoS One; 2016; 11(8):e0160192. PubMed ID: 27483366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral Decay Dynamics and Mathematical Modeling of Treatment Response: Evidence of Lower in vivo Fitness of HIV-1 Subtype C.
    Shet A; Nagaraja P; Dixit NM
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):245-251. PubMed ID: 27273158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART.
    Sedaghat AR; Siliciano JD; Brennan TP; Wilke CO; Siliciano RF
    PLoS Pathog; 2007 Aug; 3(8):e122. PubMed ID: 17784786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus.
    Chun TW; Justement JS; Moir S; Hallahan CW; Maenza J; Mullins JI; Collier AC; Corey L; Fauci AS
    J Infect Dis; 2007 Jun; 195(12):1762-4. PubMed ID: 17492591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations.
    Deng K; Pertea M; Rongvaux A; Wang L; Durand CM; Ghiaur G; Lai J; McHugh HL; Hao H; Zhang H; Margolick JB; Gurer C; Murphy AJ; Valenzuela DM; Yancopoulos GD; Deeks SG; Strowig T; Kumar P; Siliciano JD; Salzberg SL; Flavell RA; Shan L; Siliciano RF
    Nature; 2015 Jan; 517(7534):381-5. PubMed ID: 25561180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
    Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
    mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.